#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13746	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2399	689.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1446	1446	C	885	C,T,G	881,2,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13746	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2399	689.9	0	HET	.	.	.	C260T,A	.	260	260	C	522	522	C	790	C,T,A	630,159,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22572	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4023	699.5	0	.	n	.	0	T695C	SNP	695	695	T	1273	1273	C	808	C,G	806,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22572	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4023	699.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1915	1915	A	917	A,G,C	915,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22572	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4023	699.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2549	2549	C	740	C,T	739,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22572	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4023	699.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3175	3175	T	781	T,G,A	776,4,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22572	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4023	699.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2623	2623	A	693	A,G	691,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2030	folP	852	852	100.0	folP.l15.c4.ctg.1	2030	124.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1269	1271	AGC	199;199;199	A,C;G;C,G,A	197,1;199;197,1,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5242	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3776	172.9	1	SNP	p	S91F	0	.	.	271	273	TCC	757	759	TCC	199;201;204	T;C;C	199;201;204	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5242	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3776	172.9	1	SNP	p	D95G	0	.	.	283	285	GAC	769	771	GAC	204;204;205	G;A;C	204;204;205	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5242	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3776	172.9	1	SNP	p	D95N	0	.	.	283	285	GAC	769	771	GAC	204;204;205	G;A;C	204;204;205	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1952	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1703	142.5	1	SNP	p	G45D	1	.	.	133	135	GAC	672	674	GAC	237;235;232	G;A;C,T	237;235;231,1	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1120	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1462	95.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4990	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3324	186.8	1	SNP	p	D86N	0	.	.	256	258	GAC	766	768	GAC	232;230;233	G,T;A;C	231,1;230;233	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4990	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3324	186.8	1	SNP	p	S87W	0	.	.	259	261	AGT	769	771	AGT	234;237;239	A;G;T	234;237;239	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4990	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3324	186.8	1	SNP	p	S87R	0	.	.	259	261	AGT	769	771	AGT	234;237;239	A;G;T	234;237;239	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4990	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3324	186.8	1	SNP	p	S87I	0	.	.	259	261	AGT	769	771	AGT	234;237;239	A;G;T	234;237;239	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4990	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3324	186.8	1	SNP	p	S88P	0	.	.	262	264	TCC	772	774	TCC	240;239;240	T,G;C;C	238,2;239;240	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4216	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3135	167.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1796	1798	GGC	219;217;214	G;G,T;C	219;216,1;214	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1458	1460	GCA	217;216;215	G;C;A,C	217;216;214,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1461	1463	ATC	214;214;211	A;T;C,G,A	214;214;209,1,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1473	1475	GTG	210;210;210	G,T;T;G	209,1;210;210	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1473	1475	GTG	210;210;210	G,T;T;G	209,1;210;210	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1977	1979	ACC	215;218;217	A;C;C	215;218;217	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2031	2033	GCG	175;176;174	G,C;C,T;G,T	174,1;175,1;173,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2031	2033	GCG	175;176;174	G,C;C,T;G,T	174,1;175,1;173,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2154	2156	GGC	196;200;199	G;G;C	196;200;199	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2163	2165	GGC	207;209;212	G,T;G;C	206,1;209;212	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3738	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2847	163.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2181	2183	CCG	209;209;210	C,G;C,A;G,A	206,3;208,1;209,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5234	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3556	183.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2444	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2257	134.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	824	824	C	191	C,G	190,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	S271T	NONSYN	811	813	TCG	49	51	ACT	73;73;73	A;C;T	69;69;69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	55	57	GAT	73;73;73	G;A;T	69;69;69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	58	60	AGT	73;73;73	A;G;T	69;69;69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	N277H	NONSYN	829	831	AAC	67	69	CAC	73;73;73	C;A;C	69;69;69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	R307E	NONSYN	919	921	AGA	157	159	GAA	3;3;3	G;A;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	T311A	NONSYN	931	933	ACA	169	171	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	E312D	NONSYN	934	936	GAA	172	174	GAC	4;4;4	G;A;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	F314I	NONSYN	940	942	TTC	178	180	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	A316S	NONSYN	946	948	GCG	184	186	TCG	4;4;4	T;C;G	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	V318A	NONSYN	952	954	GTC	190	192	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	G319S	NONSYN	955	957	GGC	193	195	AGC	4;4;4	A;G;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	G320A	NONSYN	958	960	GGT	196	198	GCC	4;3;3	G;C;C	4;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	346	porB1a	984	222	90.09	porB1a.l15.c17.ctg.2	290	34.8	0	.	p	.	0	G322V	NONSYN	964	966	GGT	202	204	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	G38E	NONSYN	112	114	GGA	639	641	GAA	215;214;214	G;A;A	215;214;214	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	669	671	GGA	228;230;236	G;G,A;A	228;229,1;236	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	786	788	GCT	247;247;248	G,T;C,A;T,C	246,1;246,1;247,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	792	794	AGC	243;238;239	A;G;C	243;238;239	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	884	885	CG	237;238	C;G,T	237;237,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	887	889	CAG	237;237;233	C;A;G	237;237;233	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	891	893	AAA	231;227;224	A;A,C;A	231;226,1;224	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	954	956	GAA	233;233;235	G,T;A;A	232,1;233;235	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	978	980	GCA	245;245;245	G;C,T;A	245;244,1;245	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1161	1163	GAT	268;269;269	G;A;T	268;269;269	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1164	1166	GGT	271;268;263	G,T;G;T,G	270,1;268;262,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1179	1181	ATG	255;255;252	A;T;G	255;255;252	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1293	1295	GCA	200;201;200	G,A,T;C;A	198,1,1;201;200	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1296	1298	ACG	202;203;204	A;C;G,T	202;203;203,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1299	1301	GGG	208;211;210	G;G;G,T,A	208;211;208,1,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1302	1304	GTT	211;210;210	G,T,A;T,A;T,C	209,1,1;209,1;209,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1362	1364	GTA	246;241;240	G,T;T,G;A	244,1;239,1;239	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1401	1403	ACT	249;249;248	A;C;T	249;249;248	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1407	1409	GAT	255;254;255	G,T;A;T	254,1;254;255	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1419	1421	CAC	273;273;272	C;A;C	273;273;272	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	1	SNP	p	G120K	1	.	.	358	360	AAG	884	886	CGG	237;238;238	C;G,T;G,A	237;237,1;237,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	1	SNP	p	A121D	1	.	.	361	363	GAC	887	890	CGC	237;233;234	C;G;C	237;233;234	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2834	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1744	201.5	1	SNP	p	D121N	0	.	.	361	363	GAC	887	890	CGC	237;233;234	C;G;C	237;233;234	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9286	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5433	213.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2315	2317	AAT	283;286;283	A,C;A,C;T	281,1;284,1;282	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1416	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1542	114.6	1	SNP	p	V57M	1	.	.	169	171	ATG	738	740	ATG	255;259;259	A;T,G;G,T	255;258,1;258,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
